All the news Showing 10 of 15 articles from: New and experimental treatments for hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Vir's hep B drug, poised for combo trials, shows promise in phase 2 Fierce Biotech / 28 April 2020 Hepatitis B Foundation Plans Externally-Led Patient-Focused Drug Development Meeting for Chronic Hepatitis B in June 2020 Hepatitis B Foundation / 11 December 2019 Therapeutic hepatitis B vaccine may lead to functional cure Liz Highleyman / 13 November 2019 An experimental therapeutic vaccine called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen (HBsAg) levels, according to study presented this week ... Roche takes aim at hepatitis B, striking R&D deal with Dicerna Biopharma Dive / 12 November 2019 Arbutus cans early-phase hep B program after 2 healthy people fall ill Fierce Biotech / 24 October 2019 Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Hepatitis B capsid inhibitors look promising in early studies Liz Highleyman / 18 April 2018 Two experimental drugs that interfere with assembly of the hepatitis B virus (HBV) capsid and prevent production of functional new virus demonstrated good safety and promising antiviral activity in early clinical trials, according ... GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B Liz Highleyman / 08 December 2016 An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ... Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... New Tenofovir Formulation Provides Safer Hepatitis B Treatment Medscape (free registration required) / 03 October 2016 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds